Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tate & Lyle pleased by volume momentum

(Sharecast News) - Tate&Lyle reported an increase in operating profits at the start of its 2025 fiscal year. That was despite the drag on the topline at its Food & Beverage solutions unit, although revenue growth at Sucralose was described as "good".

All in all, in a trading statement for the three months ending on 30 June the food ingredients maker said that group performance had met management's expectations.

It's encouraging to see volume momentum across the business, and we continue to expect volume growth to accelerate as the 2025 financial year progresses," the company's chief executive officer, Nick Hampton, said.

"Planning for the integration of Tate & Lyle and CP Kelco is progressing well with both organisations excited about the opportunity to deliver significantly greater value for customers and the growth potential of the combined business. We look forward to the future with confidence."

On 20 June the company had announced its intention to acquire CP Kelco, the pectin provider, for $1.8bn (£1.4bn).

Ahead of its AGM, the company also reiterated guidance for a dip in revenues on a constant currency basis while earnings before interest, taxes, depreciation and amortisation were seen rising by 4-7%.

As at 24 July, the company had repurchased 6.7m of its own shares at a cost of £42m as part of the £215m share buyback programme unveiled on 20 June.

Shares in Tate&Lyle were adding 0.86% to 648.50p as of 1510 BST.

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.